Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (Alliance) N9831

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5798-5807

  Dueck, Amylou C ^a   Reinholz, Monica M ^b   Geiger, Xochiquetzal J ^c   Tenner, Kathleen ^b   Ballman, Karla ^b   Jenkins, Robert B ^b   Riehle, Darren ^b   Chen, Beiyun ^b   McCullough, Ann E ^a   Davidson, Nancy E ^d   Martino, Silvana ^e   Sledge, George W ^f   Kaufman, Peter A ^g   Kutteh, Leila A ^h   Gralow, Julie ⁱ   Harris, Lyndsay N ^j   Ingle, James N ^b   Lingle, Wilma L ^b   Perez, Edith A ^c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e Angeles Clinic and Research Institute   (United States)

^f INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^h Oncology Associates of Cedar Rapids   (United States)

ⁱ SEATTLE CANCER CARE ALLIANCE   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MYC PROTEIN; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886423250     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0558     Document Type: Article

References (49)

1. Perez EA, Palmieri FM, Brock SM. Trastuzumab. Cancer Treat Res 2009;151:181-96.
2. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-73.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
4. Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets 2009;9:148-62.
5. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer 2000;7:143-64.
6. Lutz W, Leon J, Eilers M. Contributions of Myc to tumorigenesis. Biochim Biophys Acta 2002;1602:61-71.
7. Xu J, Chen Y, Olopade OI. MYC and Breast Cancer. Genes Cancer 2010;1:629-40.
8. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000;19:1647-56.
9. Kim C, Bryant J, Horne Z, Geyer C, Wickerham D, Wolmark N, et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. [Abstract 46]. Breast Cancer Res Treat 2005;94:S6.
10. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol 2011;29:651-9.
11. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011;29:4491-7.
12. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005;23:7265-77.
13. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002; 77:148-54.
14. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25: 118-45.
15. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res 1995;15:959-64.
16. Dang CV. Enigmatic MYC conducts an unfolding systems biology symphony. Genes Cancer 2010;1:526-31.
17. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8:976-90.
18. Locker AP, Dowle CS, Ellis IO, Elston CW, Blamey RW, Sikora K, et al. c-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer 1989;60:669-72.
19. Mizukami Y, Nonomura A, Noguchi M, Taniya T, Koyasaki N, Saito Y, et al. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas. Anticancer Res 1991;11: 1485-94.
20. Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA, et al. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res 1992;52: 2597-602.
21. Spandidos DA, Yiagnisis M, Papadimitriou K, Field JK. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer. Anticancer Res 1989; 9:1385-93.
22. Spaventi R, Kamenjicki E, Pecina N, Grazio S, Pavelic J, Kusic B, et al. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-Hras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression. In Vivo 1994;8: 183-9.
23. Walker RA, Senior PV, Jones JL, Critchley DR, Varley JM. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. J Pathol 1989;158: 97-105.
24. Naidu R, Wahab NA, Yadav M, Kutty MK. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 2002;9:189-96.
25. Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer 2004;90:1612-9.
26. Liao DJ, Natarajan G, Deming SL, Jamerson MH, Johnson M, Chepko G, et al. Cell cycle basis for the onset and progression of c-Mycinduced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Oncogene 2000;19:1307-17.
27. Pavelic ZP, Steele P, Preisler HD. Evaluation of c-myc proto-oncogene in primary human breast carcinomas. Anticancer Res 1991;11:1421-7.
28. Miller TL, Huzel NJ, Davie JR, Murphy LC. C-myc gene chromatin of estrogen receptor positive and negative breast cancer cells. Mol Cell Endocrinol 1993;91:83-9.
29. Saccani Jotti G, Fontanesi M, Bombardieri E, Gabrielli M, Veronesi P, Bianchi M, et al. Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology. Int J Biol Markers 1992;7:35-42.
30. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995;221: 706-18.
31. Bolufer P, Molina R, Ruiz A, Hernandez M, Vazquez C, Lluch A. Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer. Clin Chim Acta 1994;229:107-22.
32. Sirotkovic-Skerlev M, Krizanac S, Kapitanovic S, Husnjak K, Unusic J, Pavelic K. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Exp Mol Pathol 2005;79:42-50.
33. Guerin M, Barrois M, Terrier MJ, Spielmann M, Riou G. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res 1988; 3:21-31.
34. Pertschuk LP, Feldman JG, Kim DS, Nayeri K, Eisenberg KB, Carter AC, et al. Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer. Cancer 1993;71:162-71.
35. Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M. Determination of cmyc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer 1999;81:1385-91.
36. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 1999; 59:2759-65.
37. Arteaga CL. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors? J Clin Oncol 2006;24:3722-5.
38. Henson ES, Hu X, Gibson SB. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006;12:845-53.
39. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45.
40. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003;22:9007-21.
41. Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 1999;18: 2916-24.
42. Zhao Y, Zhou LM, Chen YY, Yang SG, Tian WM. MYC genes with differential responses to tapping, mechanical wounding, ethrel and methyl jasmonate in laticifers of rubber tree (Hevea brasiliensis Muell. Arg.). J Plant Physiol 2011;168:1649-58.
43. Okuyama H, Endo H, Akashika T, Kato K, InoueM. Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res 2010;70: 10213-23.
44. Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999;187:207-16.
45. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker? Cancer 2003;97:1321-31.
46. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11:174-83.
47. Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 2006;24:3735-46.
48. Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, et al. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 Trial. J Clin Oncol 2013;31:2115-22.
49. Reinholz MM, Dueck AC, Chen B, Geiger X, McCullough AE, Jenkins RB, et al. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2? breast cancer in NCCTG adjuvant trial N9831. J Clin Oncol 2011;29(15 suppl): 10503.